Stay updated on Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.

Latest updates to the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedNew history entries for Contacts/Locations and Study Status were added (dated 2025-12-30 and 2025-12-23), and an entry from 2025-11-13 was removed.SummaryDifference0.3%

- Check18 days agoChange DetectedThe new page adds a 'Revision: v3.3.3' note in the footer and removes 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'; these are minor site policy/version updates that do not affect the study record or user-facing trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedThe history page now displays Revision: v3.3.2 and no longer shows Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedVersion added on 2025-11-13 includes updated Contacts/Locations and an updated Study Status.SummaryDifference0.7%

- Check69 days agoChange DetectedThe history table now includes additional versions with updated study status and related changes. The new screenshot shows more recent submission dates added to the record history.SummaryDifference0.1%

- Check97 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference10%

Stay in the know with updates to Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of IV ABBV-383 in Multiple Myeloma Clinical Trial page.